Actively Recruiting
Pharmacokinetic Study of Tranexamic Acid
Led by Zhejiang Cancer Hospital · Updated on 2024-12-11
30
Participants Needed
1
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Tranexamic acid is an effective anti fibrinolytic drug. Clinical studies have found that intravenous injection of tranexamic acid is more effective in reducing blood loss and transfusion in patients with advanced ovarian cancer, without increasing the risk of postoperative complications. Different surgeries and administration routes have an impact on the pharmacokinetics and pharmacodynamics of TXA. At present, there is little data on the pharmacokinetics of intramuscular injection of TXA, and almost all of the data comes from males. For ovarian cancer patients, there are currently no reports on the pharmacokinetics of TXA through different routes of administration, such as intramuscular and intravenous administration. Therefore, the investigators chose ovarian cancer patients and administered it through different routes of intravenous and intramuscular injection.
CONDITIONS
Official Title
Pharmacokinetic Study of Tranexamic Acid
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult women aged 20-64 diagnosed with advanced ovarian cancer undergoing cytoreductive surgery
- Cancer stage III or IV
- ASA (American Society of Anesthesiologists) physical status classification II or III
- Surgery duration longer than 2 hours
You will not qualify if you...
- Renal dysfunction with serum creatinine above 200 mmol/L
- Liver dysfunction with Child Turcote classification greater than 6
- History of serious mental illness, epilepsy, or visual impairment
- Previous or current bleeding disorders, coagulation problems, or thromboembolic events
- Presence of lower limb venous thrombosis
- Use of anticoagulants or antifibrinolytic drugs before surgery within the past month
- Allergy to tranexamic acid
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
Y
Yejing Zhu, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here